Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $108 to $72.
Needham Maintains Buy on Cytokinetics, Lowers Price Target to $72
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.